Clinical significance of serum sRAGE and esRAGE in women with normal pregnancy and preeclampsia

Journal of Perinatal Medicine

Volumn 39, Issue 5, 2011, Pages 507-513

  Kwon, Jae Hyun ^a   Kim, Young Han ^a   Kwon, Ja Young ^a   Park, Yong Won ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

esRAGE; preeclampsia; sRAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ENDOGENOUS SECRETORY RECEPTOR OF ADVANCED GLYCATION END PRODUCT; SOLUBLE RECEPTOR OF ADVANCED GLYCATION END PRODUCT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THIRD TRIMESTER PREGNANCY;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, THIRD; RECEPTORS, IMMUNOLOGIC; REFERENCE VALUES; SOLUBILITY;

EID: 80052778113     PISSN: 03005577     EISSN: 16193997     Source Type: Journal    
DOI: 10.1515/JPM.2011.055     Document Type: Article

References (50)

1. American College of Obstetricians and Gynecologists Committee on Obstetric Practice. Diagnosis and management of preeclampsia and eclampsia. Int J Gynecol Obstet. 2002;77: 67-75.
2. Arikan S, Konukoglu D, Arican C, Akcay T, Davas T. Lipid peroxidation and antioxidant status in maternal and cord blood. Gynecol Obstet Invest. 2001;51:145-9.
3. Basta G, Leonardis D, Mallamaci F, Cutrupi S, Pizzini P, Gaetano L, et al. Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney Int. 2010;77: 225-31.
4. Belo L, Santos-Silva A, Rocha S, Caslake M, Cooney J, Pereira-Leite L, et al. Fluctuations in C-reactive protein concentration and neutrophil activation during normal human pregnancy. Eur J Obstet Gynecol Reprod Biol. 2005;123: 46-51.
5. Brown LF, Fraser CG. Assay validation and biological variation of serum receptor for advanced glycation end-products. Ann Clin Biochem. 2008;45:518-9.
6. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318:315-21.
7. Bucciarelli LG, Kaneko M, Ananthakrishnan R, Harja E, Lee LK, Hwang YC, et al. Receptor for advanced-glycation end products: Key modulator of myocardial ischemic injury. Circulation. 2006;113:1226-34.
8. Chekir C, Nakatsuka M, Noguchi S, Konishi H, Kamada Y, Sasaki A, et al. Accumulation of advanced glycation end products in women with preeclampsia: Possible involvement of placental oxidative and nitrative stress. Placenta. 2006;27: 225-33.
9. Cooke CL, Brockelsby JC, Baker PN, Davidge ST. The receptor for advanced glycation end products (RAGE) is elevated in women with preeclampsia. Hypertens Pregnancy. 2003;22: 173-84.
10. Dattilo BM, Fritz G, Leclerc E, Kooi CW, ClausW, Heizmann CW, et al. The extracellular region of the receptor for advanced glycation end products is comprised of two independent structural units. Biochemistry. 2007;46:6957-70.
11. Emanuele E, D'Angelo A, Tomaino C, Binetti G, Ghidoni R, Politi P, et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol. 2005;62:1734-6.
12. Falcone C, Emanuele E, D'Angelo A, Buzzi MP, Belvito C, Cuccia M, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in non-diabetic men. Arterioscler Thromb Vasc Biol. 2005;25: 1032-7.
13. Fialová L, Malbohan I, Kalousová M, Soukupová J, Krofta L, Stípek S, et al. Oxidative stress and inflammation in pregnancy. Scand J Clin Lab Invest. 2006;66:121-7.
14. Germanová A, Koucký M, Hájek Z, Parízek A, Zima T, Kalousová M. Soluble receptor for advanced glycation end products in normalal and pathological pregnancy. Clin Biochem. 2010;43:442-6.
15. Geroldi D, Falcone C, Emanuele E, D'Angelo A, Calcagnino M, Buzzi MP, et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens. 2005;23:1725-9.
16. Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: From disease marker to potential therapeutic target. Curr Med Chem. 2006;13:1971-8.
17. Gohda T, Tanimoto M, Moon JY, Gotoh H, Aoki T, Matsumoto M, et al. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function. Diabetes Res Clin Pract. 2008;81:196-201.
18. Hájek Z, Germanová A, Koucký M, Zima T, Kopecký P, Vítkova M, et al. Detection of feto-maternal infection/inflammation by the soluble receptor for advanced glycation end products (sRAGE): Results of a pilot study. J Perinat Med. 2008;36:399-404.
19. Hanford LE, Enghild JJ, Valnickova Z, Petersen SV, Schaefer LM, Schaefer TM, et al. Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J Biol Chem. 2004;279:50019-24.
20. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999;97:889-901.
21. Hudson BI, Carter AM, Harja E, Kalea AZ, Arriero M, Yang H, et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J. 2008;22:1572-80.
22. Kalea AZ, Schmidt AM, Hudson BI. RAGE: A novel biological and genetic marker for vascular disease. Clin Sci. 2009; 116:621-37.
23. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Yasuda T, et al. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetest patients. Diabetes Vasc Dis Res. 2008;5: 190-7.
24. Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: Role in vascular disease of diabetes and aging. Proc Natl Acad Sci USA. 1990;87:9010-4.
25. Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S, et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol. 2005;25:2587-93.
26. Marcovecchio ML, Giannini C, Dalton RN, Widmer B, Chiarelli F, Dunger DB. Reduced endogenous secretory receptor for advanced glycation end products (esRAGE) in young people with type 1 diabetes developing microalbuminuria. Diabet Med. 2009;26:815-9.
27. Morris JM, Gopaul NK, Endresen MJ, Knight M, Linton EA, Dhir S, et al. Circulating markers of oxidative stress are raised in normal pregnancy and pre-eclampsia. Br J Obstet Gynaecol. 1998;105:1195-9.
28. Nakamura K, Yamagishi SI, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, et al. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev. 2007;23:368-71.
29. Nakatsuka M, Takata M, Tada K, Asagiri K, Habara T, Noguchi S, et al. A long-term transdermal nitric oxide donor improves uteroplacental circulation in women with preeclampsia. J Ultrasound Med. 2002;21:831-6.
30. Palm M, Axelsson O, Wernroth L, Basu S. F(2)-isoprostanes, tocopherols and normal pregnancy. Free Radic Res. 2009; 43:546-52.
31. Park IH, Yeon SI, Youn JH, Choi JE, Sasaki N, Choi IH, et al. Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. Mol Immunol. 2004;40:1203-11.
32. Pertyńska-Marczewska M, G{lowacka E, Sobczak M, Cypryk K, Wilczyński J. Glycation endproducts, soluble receptor for advanced glycation endproducts and cytokines in diabetic and non-diabetic pregnancies. Am J Reprod Immunol. 2009;61: 175-82.
33. Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther. 2005;7:817-24.
34. Rodriguez-Garcia J, Requena JR, Rodriguez-Segade S. Increased concentrations of serum pentosidine in rheumatoid arthritis. Clin Chem. 1998;44:250-5.
35. Rong LL, Yan SF, Wendt T, Hans D, Pachydaki S, Bucciarelli LG, et al. RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways. FASEB J. 2004;18:1818-25.
36. Sakaguchi T, Yan SF, Yan SD, Belov D, Rong LL, Sousa M, et al. Arterial restenosis: Central role of RAGE dependent neointimal expansion. J Clin Invest. 2003;111:959-72.
37. Schlueter C, Hauke S, Flohr AM, Rogalla P, Bullerdiek J. Tissue-specific expression patterns of the RAGE receptor and its soluble forms -a result of regulated alternative splicing? Biochim Biophys Acta. 2003;1630:1-6.
38. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem. 1992;267:14987-97.
39. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascularlesions. Arterioscler Thromb. 1994;14:1521-8.
40. Schmidt AM, Mora R, Cap R, Yan SD, Brett J, Ramakrishnan R, et al. The endothelial cell binding site for advanced glycation end products consists of a complex: An integral membrane protein and a lactoferrin-like polypeptide. J Biol Chem. 1994;269:9882-8.
41. Schmidt AM, Yan SD, Wautier JL, Stern DM. Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res. 1999;84:489-97.
42. Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta. 2000;1498:99-111.
43. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001;108:949-55.
44. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: A review. Diabetologia. 2001;44:129-46.
45. Takagi Y, Nikaido T, Toki T, Kita N, Kanai M, Ashida T, et al. Levels of oxidative stress and redox-related molecules in the placenta in preeclampsia and fetal growth restriction. Virchows Arch. 2004;444:49-55.
46. Toescu V, Nuttall SL, Martin U, Kendall MJ, Dunne F. Oxidative stress and normal pregnancy. Clin Endocrinol. 2002; 57:609-13.
47. Williams MA, Mahomed K, Farrand A, Woelk GB, Mudzamiri S, Madzime S, et al. Plasma tumor necrosis factor-alpha soluble receptor p55 (sTNFp55) concentrations in eclamptic, preeclamptic and normotensive pregnant Zimbabwean women. J Reprod Immunol. 1998;40:159-73.
48. Yamagishi S, Matsui T. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci. 2010;2:1184-95.
49. Yamamoto M, Yamaguchi T, Yamauchi M, Sugimoto T. Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes. Diabetes Care. 2009;32: 2263-8.
50. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J. 2003;370:1097-9.